Innate Pharma (Nasdaq: IPHA) reports 93.9M shares and voting rights update

Rhea-AI Filing Summary

Innate Pharma S.A. released an update on its capital structure and voting rights as of April 9, 2026. The company reports 93,860,680 shares outstanding, made up mainly of ordinary shares with small tranches of 2016 and 2017 preferred shares.

The company states it has 94,484,443 theoretical voting rights, used for regulatory threshold calculations in France, and 94,465,868 exercisable voting rights, which exclude treasury shares with suspended voting rights. The update helps clarify shareholder voting power ahead of any future corporate decisions.

Key Figures

Shares outstanding: 93,860,680 shares Ordinary shares: 93,847,763 shares Preferred Shares 2016: 5,336 shares +4 more

7 metrics

Shares outstanding 93,860,680 shares Total shares outstanding as of April 9, 2026

Ordinary shares 93,847,763 shares Ordinary shares included in total outstanding

Preferred Shares 2016 5,336 shares Preferred Shares 2016 included in capital

Preferred Shares 2017 7,581 shares Preferred Shares 2017 included in capital

Theoretical voting rights 94,484,443 rights Gross voting rights for threshold calculations

Exercisable voting rights 94,465,868 rights Net voting rights excluding treasury shares

AGAP 2016 voting rights 241 voting rights 130 for AGAP 2016-1 and 111 for AGAP 2016-2

Key Terms

theoretical voting rights, exercisable voting rights, Preferred Shares 2016, Preferred Shares 2017, +2 more

6 terms

theoretical voting rights financial

"Total number of theoretical voting rights (1): 94,484,443"

Theoretical voting rights are the share of control an investor would have if all possible sources of additional shares—such as stock options, warrants and convertible bonds—were turned into ordinary shares. Investors care because this “what-if” number shows potential dilution of current owners and the maximum voting power others could gain, helping assess control risk and how future actions might change company decisions, like a snapshot of ownership if every coupon were cashed in.

exercisable voting rights financial

"Total number of exercisable voting rights (2): 94,465,868"

Exercisable voting rights are the actual, usable votes attached to a security or position that allow the holder to influence company decisions at shareholder meetings—for example electing the board or approving mergers. They matter to investors because the number of votes someone can cast determines who controls the company and its strategy, similar to having usable tickets at a town meeting rather than placeholders, and can affect share value, takeover risk and how much influence minority holders have.

Preferred Shares 2016 financial

"5,336 Preferred Shares 2016"

Preferred Shares 2017 financial

"7,581 Preferred Shares 2017"

Universal Registration Document regulatory

"section of the Universal Registration Document filed with the French Financial Markets Authority"

A universal registration document is a single, comprehensive filing that collects a publicly traded company's key disclosures — such as business description, financial statements, risk factors, governance and legal information — into one place for regulators and investors. Think of it as a detailed owner’s manual and scorecard combined: it saves time when the company issues new shares or bonds and helps investors compare, check risks, and make informed decisions without hunting through many separate reports.

immunotherapies for cancer patients medical

"a global, clinical-stage biotechnology company developing immunotherapies for cancer patients"

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: Thursday April 13, 2026

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]

EXHIBIT INDEX

Exhibit Description

99.1 Press Release dated April 13, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: April 13, 2026    By:    /s/ JONATHAN DICKINSON     Name:    Jonathan Dickinson

Title:    Chief Executive Officer

EXHIBIT 99.1

Number of shares and voting rights of Innate Pharma as of April 9, 2026

Marseille, France, April 13, 2026, 7:00 A.M. CEST

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of April 9, 2026:

Total number of shares outstanding: 93,860,680 shares

including :    

93,847,763 ordinary shares

5,336 Preferred Shares 2016

7,581 Preferred Shares 2017

Total number of theoretical voting rights (1): 94,484,443

Total number of exercisable voting rights (2): 94,465,868

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About Innate Pharma:

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X. 

Information about Innate Pharma shares:

ISIN code: FR0010331421

Ticker code: Euronext: IPH Nasdaq: IPHA

LEI: 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. 

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. 

For additional information, please contact:

Investors & Media Relations

Innate Pharma 

Stéphanie Cornen 

stephanie.cornen@innate-pharma.fr 

Investor Relations

investors@innate-pharma.fr 

Media

communication@innate-pharma.fr

FAQ

How many Innate Pharma (IPHA) shares were outstanding on April 9, 2026?

Innate Pharma had 93,860,680 shares outstanding as of April 9, 2026. This total includes the company’s ordinary shares plus small series of preferred shares issued in 2016 and 2017, forming the basis for shareholder equity and voting calculations.

What are Innate Pharma IPHA’s theoretical voting rights as of April 9, 2026?

Theoretical voting rights totaled 94,484,443 on April 9, 2026. These “gross” voting rights include all shares with attached votes, even where voting is suspended, and are used by French regulators to monitor shareholding threshold crossings for disclosure purposes.

What are Innate Pharma (IPHA) exercisable voting rights as of April 9, 2026?

Exercisable voting rights were 94,465,868 on April 9, 2026. This “net” figure excludes treasury shares held by the company that carry suspended voting rights, and represents the actual voting power that can be used in shareholder meetings.

How is Innate Pharma’s 93,860,680 share count composed?

Innate Pharma’s 93,860,680 outstanding shares include 93,847,763 ordinary shares, 5,336 Preferred Shares 2016, and 7,581 Preferred Shares 2017. This breakdown shows ordinary shares dominate the capital, with preferred series forming only a very small portion.

What kind of company is Innate Pharma (IPHA)?

Innate Pharma is a clinical-stage biotechnology company focused on immunotherapies for cancer. It develops next-generation antibody therapeutics, including candidates like IPH4502, lacutamab, and monalizumab, and collaborates with partners such as AstraZeneca and Sanofi in immuno-oncology.

On which stock exchanges are Innate Pharma shares traded?

Innate Pharma shares trade on Euronext Paris and Nasdaq. The company’s ticker is IPH on Euronext and IPHA on Nasdaq, with ISIN code FR0010331421, providing access for both European and U.S. investors to trade the stock.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 14.7 KB